Developing bispecific antibodies for the treatment of immunological and inflammatory (I&I) disorders
Founded in 2024 by by Dr. Shanshan Xu and Helmut Jeggle, Bambusa Therapeutics is a rapidly growing biotechnology company specializing in developing transformative inflammatory and immunological therapeutics.
Based in the vibrant Boston Seaport area, our mission is to advance the field of immunology with cutting-edge solutions.
Our Team
We founded Bambusa Therapeutics with a belief that the I&I field is long overdue for innovative approaches and transformative therapeutics.
Since our inception, we have built a diverse portfolio of molecules and are uniquely positioned to make significant contributions to patients suffering from debilitating and chronic inflammatory conditions.
~ Shanshan Xu, MD, PhD
Chief Executive Officer and Founder
Thang Ho
SVP of Development Science
Isabelle Müldner
Interim CFO
Wenbing Hu
VP of CMC
Crystal MacKay
VP, Chief of Staff
Pipeline
Board of Directors
Shanshan Xu, MD, PhD
CEO, Founder
Helmut Jeggle
Director, Co-Founder
Derek DiRocco, PhD
Director
Sean Marett
Director, BD Advisor
One Marina Park Drive
Suite 1410
Boston, MA 02210
info@bambusatx.com
